What drove ALGS' earnings surge in Q3 2024?

ALigos Therapeutics, Inc. (NASDAQ: ALGS) experienced a significant earnings surge in Q3 2024, with a reported EPS of -$3.07 and total revenue of $1.27 million for the quarter. While the company posted a negative net margin of 783.72% and a negative return on equity of 144.16%, the revenue figure represents an increase from the previous quarter's revenue of $0.99 million. The surge in earnings can be attributed to **Increased Clinical Trial Expenses**. The company's recent business progress includes completing enrollment ahead of schedule for the Phase 2a HERALD study of its THR-β agonist drug candidate, ALG-055009, with topline data expected in early Q4 2024. Additionally, the Phase 1b trial for ALG-000184 in chronic hepatitis B patients showed consistent, potent antiviral activity, with sustained HBV DNA suppression reported. These advancements in clinical trials suggest that the company's research and development efforts are progressing, which could lead to increased funding and potential revenue in the future.